Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma, Ewing 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1

Interventions

Vincristine 4X-Rays 3Phantoms, Imaging 3Magnetic Resonance Spectroscopy 3Doxorubicin 3Cyclophosphamide 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2ivosidenib 2cabozantinib 2Vemurafenib 2Specimen Handling 2Peripheral Blood Stem Cell Transplantation 2Nuclear Medicine Department, Hospital 2LY3023414 2Filgrastim 2Etoposide 2pegfilgrastim 1oncogene protein E7, Human papillomavirus type 16 1olaparib 1lexatumumab 1larotrectinib 1ganitumab 1fludarabine phosphate 1etoposide phosphate 1erdafitinib 1ensartinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Sarcoma, Ewing × lexatumumab × Clear all
NCT00428272 2019-12-17

HGS-ETR2 to Treat Children With Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
30 enrolled
CNSSarcoma

Neoplasm Metastasis, Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡